NEW YORK, June 30 — Tyra Biosciences, Inc. (NASDAQ:TYRA) made the cut in a recent roundup of the 10 most promising cancer stocks according to Wall Street analysts. The figure that matters for investors now: the company is gearing up for data from its SURF302 trial.
The bottom line for TYRA shareholders is that this mid-stage study is the next major catalyst. TheFly reported the stock’s inclusion on that analyst-curated list, placing Tyra among a select group of biotech names seen as having strong upside in oncology.
By the numbers, Tyra is developing a pipeline of fibroblast growth factor receptor (FGFR) inhibitors. The lead candidate, TYRA-300, is being tested in the SURF302 trial for patients with advanced solid tumors, including urothelial cancer. Investors will note that FGFR alterations are a known driver in several cancers, and Tyra’s approach aims to improve on earlier-generation FGFR drugs that had toxicity issues.
The company has not yet released top-line results from SURF302. That data readout is the key event ahead. Wall Street analysts who flagged TYRA as promising are betting that positive efficacy and safety numbers could reset expectations for the stock.
Tyra’s strategy is to design compounds that are more selective for specific FGFR mutations, potentially offering a better therapeutic window. The SURF302 trial is an open-label, dose-escalation and expansion study. The company has guided that it expects to report initial data this year.
One short sentence: The stock trades on the promise of that data.
If the results show meaningful tumor shrinkage with manageable side effects, TYRA could become a takeover target or a commercial-stage player. If the data disappoints, the stock faces a sharp reset. That binary risk is baked into the current valuation.
Analysts on the list of most promising cancer stocks are likely looking past near-term volatility to the broader opportunity in FGFR-addicted cancers. Tyra’s second program, TYRA-200, targets FGFR2 fusions in cholangiocarcinoma, adding pipeline depth.
For now, the company remains a clinical-stage biotech with no approved products and no revenue. The SURF302 data will determine whether TYRA graduates from promising to proven.
Consult your doctor for medical advice.
